Overview of Dr. Linhares
Dr. Yuliya Linhares is an oncologist in Miami, FL and is affiliated with multiple hospitals in the area, including Baptist Hospital of Miami and Cedars-Sinai Medical Center. She received her medical degree from University of North Carolina at Chapel Hill School of Medicine and has been in practice 16 years. She is one of 113 doctors at Cedars-Sinai Medical Center and one of 58 doctors at Baptist Hospital of Miami who specialize in Oncology. She has more than 10 publications and over 50 citings.
Office
Baptist Health Miami Cancer Institute
8900 N Kendall Dr
Miami, FL 33176
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
University of North Carolina at Chapel Hill School of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2019 - 2025
CA State Medical License 2007 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Start of enrollment: 2024 Apr 25
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsOUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris
Blood Advances. 2024-12-10 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason M Melear, Ian W Flinn
Blood. 2024-12-02 - 1 citationsOutpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.Ariel Perez, Tiba Al Sagheer, George R Nahas, Yuliya P L Linhares
Frontiers in Immunology. 2024-01-01
Press Mentions
Outpatient CAR T: Safe, Effective, AccessibleNovember 1st, 2024- Outpatient Liso-Cel Administration Shows Favorable Safety in Relapsed/Refractory LBCLOctober 22nd, 2024
- Liso-Cel Has Favorable Safety Profile for Outpatients with Large B-cell LymphomaOctober 8th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
